Dyne Therapeutics (NASDAQ:DYN) Reaches New 52-Week Low – Time to Sell?

Dyne Therapeutics, Inc. (NASDAQ:DYN) hit a new 52-week low during trading on Saturday . The stock traded as low as $14.79 and last traded at $15.87, with a volume of 9825974 shares changing hands. The stock had previously closed at $23.05.

Analyst Ratings Changes

DYN has been the subject of a number of recent analyst reports. StockNews.com cut Dyne Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, September 16th. Royal Bank of Canada initiated coverage on Dyne Therapeutics in a research report on Tuesday, November 26th. They set an “outperform” rating and a $45.00 target price for the company. JPMorgan Chase & Co. cut Dyne Therapeutics from an “overweight” rating to a “neutral” rating and decreased their target price for the stock from $43.00 to $35.00 in a research report on Thursday, October 24th. Chardan Capital reiterated a “buy” rating and set a $50.00 price target on shares of Dyne Therapeutics in a report on Friday. Finally, HC Wainwright reiterated a “buy” rating and set a $55.00 price target on shares of Dyne Therapeutics in a report on Friday. One analyst has rated the stock with a sell rating, one has issued a hold rating, ten have given a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $49.91.

Dyne Therapeutics Stock Down 31.1 %

The firm has a fifty day moving average price of $27.04 and a 200 day moving average price of $34.02. The company has a market cap of $1.62 billion, a P/E ratio of -4.46 and a beta of 1.16.

Dyne Therapeutics (NASDAQ:DYN) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.96) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.71) by ($0.25). On average, sell-side analysts anticipate that Dyne Therapeutics, Inc. will post -3.44 earnings per share for the current year.

Insider Activity at Dyne Therapeutics

In other news, Director Dirk Kersten sold 23,671 shares of the firm’s stock in a transaction dated Wednesday, October 16th. The stock was sold at an average price of $35.35, for a total transaction of $836,769.85. Following the sale, the director now owns 99,652 shares of the company’s stock, valued at $3,522,698.20. This trade represents a 19.19 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Oxana Beskrovnaya sold 2,334 shares of the firm’s stock in a transaction dated Wednesday, December 11th. The stock was sold at an average price of $28.12, for a total value of $65,632.08. Following the sale, the insider now directly owns 201,685 shares in the company, valued at approximately $5,671,382.20. This represents a 1.14 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 44,742 shares of company stock worth $1,443,246 over the last 90 days. Insiders own 20.77% of the company’s stock.

Institutional Investors Weigh In On Dyne Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Rhumbline Advisers boosted its stake in shares of Dyne Therapeutics by 23.7% during the 2nd quarter. Rhumbline Advisers now owns 121,595 shares of the company’s stock worth $4,291,000 after acquiring an additional 23,266 shares during the period. Victory Capital Management Inc. bought a new position in shares of Dyne Therapeutics during the 2nd quarter worth approximately $676,000. Arizona State Retirement System boosted its stake in shares of Dyne Therapeutics by 26.9% during the 2nd quarter. Arizona State Retirement System now owns 15,070 shares of the company’s stock worth $532,000 after acquiring an additional 3,199 shares during the period. American Century Companies Inc. bought a new position in shares of Dyne Therapeutics during the 2nd quarter worth approximately $228,000. Finally, Federated Hermes Inc. boosted its stake in shares of Dyne Therapeutics by 10.4% during the 2nd quarter. Federated Hermes Inc. now owns 1,215,112 shares of the company’s stock worth $42,881,000 after acquiring an additional 114,888 shares during the period. Institutional investors and hedge funds own 96.68% of the company’s stock.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.